Cortical bone mechanical properties are altered in an animal model of progressive chronic kidney disease

PLoS ONE

Volumn 9, Issue 6, 2014, Pages

  Newman, Christopher L ^a   Moe, Sharon M ^a,b   Chen, Neal X ^a   Hammond, Max A ^c   Wallace, Joseph M ^c,d   Nyman, Jeffry S ^e,f   Allen, Matthew R ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c PURDUE UNIVERSITY   (United States)

^d Indiana University Purdue University Indianapolis   (United States)

^e VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^f DEPARTMENT OF VETERANS AFFAIRS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATOMIC FORCE MICROSCOPY; BIOMECHANICS; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CORTICAL BONE; DISEASE ASSOCIATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; NONHUMAN; OSTEOLYSIS; PHYSICAL PARAMETERS; POROSITY; PROTEIN CROSS LINKING; RAMAN SPECTROMETRY; RAT; REFERENCE POINT INDENTATION; RISK ASSESSMENT; TISSUE INJURY; YOUNG MODULUS; ANIMAL; BONE DEMINERALIZATION, PATHOLOGIC; CHEMISTRY; CHRONIC KIDNEY FAILURE; COMPLICATION; DISEASE MODEL; MECHANICS; METABOLISM; PATHOPHYSIOLOGY;

ANIMALS; BONE DEMINERALIZATION, PATHOLOGIC; COLLAGEN; DISEASE MODELS, ANIMAL; MALE; MECHANICAL PHENOMENA; MICROSCOPY, ATOMIC FORCE; RATS; RENAL INSUFFICIENCY, CHRONIC; SPECTRUM ANALYSIS, RAMAN;

EID: 84902577352     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0099262     Document Type: Article

References (59)

1. Levey AS, Eckardt KU, Tsukamoto Y, Levin A, Coresh J, et al. (2005). Definition and classification of chronic kidney disease: a position statement from Kidney Disease Improving Global Outcomes (KDIGO). Kidney Int 67:2089-2100. (Pubitemid 41623371)
2. Levin A, Bakris GL, Molitch M, Smulders M, Tian J, et al. (2007) Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int 71:31-38. (Pubitemid 44967731)
3. KDIGO Working Group (2009) KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int 76: S1-S130.
4. Cejka D, Patsch JM, Weber M, Diarra D, Riegersperger M, et al. (2011) Bone microarchitecture in hemodialysis patients assessed by HR-pQCT. Clin J Am Soc Nephrol 6:2264-71.
5. Nickolas TL, Stein E, Cohen A, Thomas V, Staron RB, et al. (2010) Bone mass and microarchitecture in CKD patients with fracture. J Am Soc Nephrol 21:1371-1380.
6. Nickolas TL, Cremers S, Zhang A, Thomas V, Stein E, et al. (2011) Discriminants of prevalent fractures in chronic kidney disease. J Am Soc Nephrol 22:1560-1572.
7. Fried LF, Biggs ML, Shlipak MG, Seliger S, Kestenbaum B, et al. (2007) Association of kidney function with incident hip fracture in older adults. J Am Soc Nephrol 18:282-286. (Pubitemid 46053440)
8. Nickolas TL, McMahon DJ, Shane E (2006) Relationship between moderate to severe kidney disease and hip fracture in the United States. J Am Soc Nephrol 17:3223-3232. (Pubitemid 44707784)
9. Nitsch D, Mylne A, Roderick PJ, Smeeth, Hubbard R, et al. (2009) Chronic kidney disease and hip-fracture-related mortality in older people in the UK. Nephrol Dial Transplant 24:1539-1544.
10. Cole JH, van der Muelen MCH (2011) Whole bone mechanics and bone quality. ClinOrthopRelat Res 469:2139-2149.
11. Seeman E, Delmas PD (2006) Bone quality: the material and structural basis of bone strength and fragility. N Engl J Med 354:2250-2261.
12. Allen MR, Chen NX, Gattone II VH, Chen X, Carr AJ, et al. (2013) Skeletal effects of zoledronic acid in an animal model of chronic kidney disease. OsteoporosInt 24:1471-1481.
13. Iwamoto J, Seki A, Sato Y, Matsumoto H (2012) Vitamin K2 improves renal function and increases femoral bone strength in rats with renal insufficiency. Calcif Tissue Int 90:50-59.
14. Iwasaki Y, Kazama JJ, Yamato H, Fukagawa M (2011) Changes in chemical composition of cortical bone associated with bone fragility in rat model with chronic kidney disease. Bone 48:1260-1267.
15. Iwasaki Y, Kazama JJ, Yamato H, Shimoda H, Fukagawa M (2013) Accumulated uremic toxins attenuate bone mechanical properties in rats with chronic kidney disease. Bone 57:477-483.
16. Jokihaara J, Porsti I, Pajamaki I, Vuohelainen T, Jolma P, et al. (2006) Paracalcitol [19-nor-1,25-(OH)2D2] in the treatment of experimental renal bone disease. J Bone Miner Res 21:745-751.
17. Moe SM, Radcliffe JS, White KE, Gattone VH II, Seifert MF, et al. (2011) The pathophysiology of early-stage chronic kidney disease-mineral bone disorder (CKD-MBD) and response to phosphate binders in the rat. J Bone Miner Res 26:2672-2681.
18. Sabbagh Y, Graciolli FG, O'Brien S, Tang W, dos Reis LM, et al. (2012) Repression of osteocyte Wnt/b-catenin signaling is an early event in the progression of renal osteodystrophy. J Bone Miner Res, 27:1757-1772.
19. Malluche HH, Porter DS, Pienkowski D (2013) Evaluating bone quality in patients with chronic kidney disease. Nat Rev Nephrol 9:671-680.
20. Kadokawa S, Matsumoto T, Naito H, Tanaka M (2011) Assessment of trabecular bone architecture and intrinsic properties of cortical bone tissue in a mouse model of chronic kidney disease. J Hard Tissue Biol 20: 79-86.
21. Moe SM, Chen NX, Seifert MF, Sinders RM, Duan D, et al. (2009) A rat model of chronic kidney disease-mineral bone disorder. Kidney Int 75:176-184.
22. Nagao S, Kugita M, Yoshihara D, Yamaguchi T (2012) Animal models for human polycystic kidney disease. Exp Anim Tokyo 61:477-488.
23. Stagner EE, Bouvrette DJ, Cheng J, Bryda EC (2009) The polycystic kidney disease-related proteins Bicc1 and SamCystin interact. BiochemBioph Res Co 383:16-21.
24. Shobeiri N, Adams MA, Holden RM (2010) Vascular calcification in animal models of CKD: a review. Am J Nephrol 31:471-481.
25. Gattone VH II, Tourkow BA, Trambaugh CM, Yu AC, Whelan S, et al. (2004)Development of multiorgan pathology in the wpk rat model of polycystic kidney disease. Anat Rec 277A:384-395. (Pubitemid 38437617)
26. Nagao S, Morita M, Kugita M, Yoshihara D, Yamaguchi T, et al. (2010) Polycystic kidney disease in Han:SPRD Cy rats is associated with elevated expression and mislocalizationof SamCystin. Am J Physiol Renal Physiol 299:F1078-F1086.
27. Aref M, Gallant MA, Organ JM, Wallace JM, Newman CL, et al. (2013) In vivo reference point indentation reveals positive effects of raloxifene on mechanical properties following 6 months of treatment in skeletally mature beagle dogs. Bone 56:449-53.
28. Hammond MA, Gallant MA, Burr DB, Wallace JM (2014) Nanoscale changes in collagen are reflected in physical and mechanical properties of bone at the microscale indiabetic rats. Bone 60:26-32.
29. Wallace JM (2012) Applications of atomic force microscopy for the assessment of nanoscale morphological and mechanical properties of bone. Bone 50:420-427.
30. Buckley A, Hill KE, Davidson JM (1988) Collagen metabolism. In:Colowick SP, Kaplan NO, Di SabatoG, editors. Methods in Enzymology: Immunochemical Techniques, Part M: Chemotaxis and inflammation. London: Academic Press. pp. 674-693.
31. Saito M, Marumo K, Fujii K, Ishioka N (1997) Single-column highperformance liquid chromatographic-fluorescence detection of immature, mature, and senescent cross-links of collagen. Anal Biochem 253:26-32 (Pubitemid 27490600)
32. Moe SM, Chen NX, Newman CL, Gattone VH II, Organ JM, et al. (2014) A comparison of calcium to zoledronic acid for improvement of cortical bone in an animal model of CKD. J Bone Miner Res 29:902-910.
33. Gallant MA, Brown DM, Organ JM, Allen MR, Burr DB (2013) Reference-point indentation correlates with bone toughness assessed using whole-bone traditional mechanical testing. Bone 53:301-305.
34. Iimori S, Mori Y, Akita W, Kuyama T, Takada S, et al. (2012) Diagnostic usefulness of bone mineral density and biochemical markers of bone turnover in predicting fracture in CKD stage 5D patients - a single-center cohort study. Nephrol Dial Transplant 27:345-351.
35. Jamal SA, Hayden JA, Beyene J (2007) Low bone mineral density and fractures in long-term hemodialysis patients: a meta-analysis. Am J Kidney Dis 49:674-681. (Pubitemid 46654494)
36. Jamal SA, Cheung AM, West SL, Lok C (2012) Bone mineral density by DXA and HR pQCT can discriminate fracture status in men and women with stages 3 to 5 chronic kidney disease. OsteoporosInt 23:2805-2813.
37. Jassal SK, von Muhlen D, Barrett-Connor E (2007) Measures of renal function, BMD, bone loss, and osteoporotic fracture in older adults: the Rancho Bernardo study. J Bone Miner Res 22:203-210. (Pubitemid 46167790)
38. Klawansky S, Komaroff E, Cavanaugh PFJr, Mitchell DY, Gordon MJ, et al. (2003) Relationship between age, renal function and bone mineral density in the US population. OsteoporosInt 14:570-576. (Pubitemid 36975556)
39. Piraino B, Chen T, Cooperstein L, Segre G, Puschett J (1988) Fractures and vertebral bone mineral density in patients with renal osteodystrophy. ClinNephrol 30:57-62.
40. Yamaguchi T, Kanno E, TsubotaJ, Shiomi T, Nakai M, et al. (1996) Retrospective study on the usefulness of radius and lumbar bone density in the separation of hemodialysis patients with fractures from those without fractures. Bone 19:549-555.
41. Diez-Perez A, Güerri R, Nogues X, Caceres E, Pena MJ, et al. (2010)Micro-Microindentationfor in vivo measurement of bone tissue mechanical properties in humans. J Bone Miner Res 25:1877-1885.
42. Güerri-Fernández RC, Nogués X, Quesada Gómez JM, Torres Del Pliego E, Puig L, et al. (2013)Microindentation for in vivo measurement of bone tissue material properties in atypical femoral fracture patients and controls. J Bone Miner Res 28:162-168.
43. Farr JN, Drake MT, Amin S, Melton LJ III, McCready LK, et al. (2014) In Vivo assessment of bone quality in postmenopausal women with type 2 diabetes. J Bone Miner Res 29:787-795.
44. Tai K, Dao M, Suresh S, Palazoglu A, Ortiz C (2007) Nanoscale heterogeneity promotes energy dissipation in bone. Nat Mater 6:454-462. (Pubitemid 46869995)
45. Phelps JB, Hubbard GB, Wang X, Agrawal CM (2000) Microstructural heterogeneity and the fracture toughness of bone. J Biomed Mater Res 51:735-741. (Pubitemid 30450734)
46. Currey J (2005) Structural heterogeneity in bone: good or bad? J MusculoskeletNeuronal Interact 5:317.
47. Aoki C, Uto K, Honda K, Kato Y, Oda H(2013) Advanced glycation end products suppress lysyl oxidase and induce bone collagen degradation in a rat model of renal osteodystrophy. Lab Invest 93:1170-1183.
48. Galli F (2007) Protein damage and inflammation in uraemia and dialysis patients. Nephrol Dial Transplant 22 (Suppl 5):v20-36.
49. Miyata T, Ueda Y, Shinzato T, Iida Y, Tanaka S, et al. (1996) Accumulation of albumin-linked and free-form pentosidine in the circulation of uremic patients with end-stage renal failure: renal implications in the pathophysiology of pentosidine. J Am Soc Nephrol 7:1198-1206. (Pubitemid 27468273)
50. Sakata N, Noma A, Yamamoto Y, Okamoto K, Meng J, et al. (2003) Modification of elastin by pentosidine is associated with the calcification of aortic media in patients with end-stage renal disease. Nephrol Dial Transplant 18:1601-1609. (Pubitemid 36939635)
51. Zoccali C, Mallamaci F, Asahia K, Benedetto FA, Tripepi G, et al. (2001) Pentosidine, carotid atherosclerosis and alterations in left ventricular geometry in hemodialysis patients. J Nephrol 14:293-298. (Pubitemid 32725281)
52. Arsov S, Graaff R, van Oeveren W, Stegmayr B, Sikole A, et al. (2014) Advanced glycation end-products and skin autofluorescence in end-stage renal disease: a review. ClinChem Lab Med 52:11-20.
53. Mitome J, Yamamato H, Saito M, Yokoyama K, Marumo K, et al. (2011)Nonenzymaticcross-linking pentosidine increase in bone collagen and are associated with disorders of bone mineralization in dialysis patients. Calcif Tissue Int 88:521-529.
54. Glenn JV, Beattie JR, Barrett L, Frizzell N, Thorpe SR, et al. (2007) Confocal Raman microscopy can quantify advanced glycation end product (AGE) modifications in Bruch's membrane leading to accurate, nondestructive prediction of ocular aging. FASEB J 21:3542-52. (Pubitemid 350075144)
55. Nyman JS, Roy A, Acuna RL, Gayle HJ, Reyes MJ, et al. (2006). Age-related effect on the concentration of collagen crosslinks in human osteonal and interstitial bone tissue. Bone 39:1210-1217. (Pubitemid 44827935)
56. Odetti P, Rossi S, Monacelli F, Poggi A, Cirnigliaro M, et al. (2005) Advanced glycationend products and bone loss during aging. Ann NY AcadSci 1043:710-717. (Pubitemid 41123964)
57. Saito M, Fujii K, Mori Y, Marumo K (2006) Role of enzymatic and glycation induced cross-links as a determinant of bone quality in spontaneously diabetic WBN/Kob rats. Osteoporosis Int 17: 1514-1523. (Pubitemid 44387486)
58. Silva MJ, Brodt MD, Lynch MA, McKenzie JA, Tanouye KM, et al. (2009) Type 1 diabetes in young rats leads to progressive trabecular bone loss, cessation of cortical bone growth, and diminished whole bone strength and fatigue life. J Bone Miner Res 24: 1618-1627.
59. Malluche HH, Porter DS, Monier-Faugere M, Mawad H, Pienkowski D (2012)Differences in bone quality in low- and high-turnover renal osteodystrophy. J Am Soc Nephrol 23:525-532.